NIH helps Tetra put the 'lid' on non-emetic PDE4 inhibitors for Alzheimer's disease
This article was originally published in Scrip
Executive Summary
A US start-up, Tetra Discovery Partners, which focuses on PDE4 modulation in the brain, has been awarded a five-year grant by the US National Institutes of Health to support work on a new drug to treat mild cognitive impairment, which often precedes and accompanies Alzheimer's disease.